The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000463370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/03/2026
Date registered
Help: Date registered
14/04/2026
Date last updated
Help: Date last updated
14/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of Laser Acupuncture on Pain Sensitivity, Cognitive Performance, and Brain Activity in Healthy Adults
Scientific title
Effects of Laser Acupuncture at Pain-Related Acupoints: Changes in Pain Sensitivity and Cognitive Performance Control, and Modulation of Brain Oscillations in Young Healthy Participants
Additional trial identifiers [1] 316457 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
brain function 340573 0
pain 340669 0
Condition category
Condition code
Alternative and Complementary Medicine 336771 336771 0 0
Other alternative and complementary medicine
Neurological 336862 336862 0 0
Studies of the normal brain and nervous system
Physical Medicine / Rehabilitation 336863 336863 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Laser acupuncture is a non-invasive therapeutic technique that applies low-level laser therapy (LLLT) to acupuncture points to stimulate physiological responses. This technique uses a laser applicator that emits low-level laser light when applied directly to the skin surface of specific acupuncture points. The participant will remain seated comfortably during the treatment.

A low-level laser device will be used to irradiate pain-related acupuncture points including Hegu (LI4), Quchi (LI11), and Zusanli (ST36). The order of acupoint stimulation will be randomized for each participant and for each session. The selected acupoints (LI4, LI11, and ST36) were chosen based on the acupoint analysis conducted in our previous Systematic review. These three acupoints were consistently identified across studies addressing pain management, pain-threshold modulation, autonomic regulation, and cortical activity in healthy participants. Therefore, these acupoints may be regarded as pain-related acupoints for investigating both behavioural and neurophysiological effects of laser acupuncture.

Each acupoint will receive 5 minutes of continuous laser stimulation per session.

Laser device: LightNeedle 300, Laser class 3B.

The parameters of the laser device are as follows:
Wavelength: 655 nm
Power output: 50 mW
Probe cable: 0.7 m
Beam divergence: 0,157 rad
Energy density: 7.5 J/cm² per point
Mode: Continuous wave

Each participant will receive four laser acupuncture sessions in total. Each complete session will last approximately 120 minutes, including pre- and post-treatment assessments.

The intervention will be delivered face-to-face in a controlled university research laboratory by a trained acupuncturist experienced in both traditional acupuncture and laser therapy. Standardized treatment protocols will be strictly followed to ensure consistency across sessions. Session fidelity will be assessed through direct observation, and adherence will be monitored by trained research personnel.

A 48-hour washout period will be implemented between different treatment conditions in accordance with the crossover trial design.

Intervention code [1] 333198 0
Treatment: Devices
Intervention code [2] 333199 0
Prevention
Description of the comparator or control
A sham laser acupuncture control will be used, where the same laser device is applied to the same acupoints without actual laser emission to maintain blinding.
Control group
Placebo

Outcomes
Primary outcome [1] 344386 0
Electroencephalography (EEG) -derived brain oscillatory measures (cortical excitability)
Timepoint [1] 344386 0
Each intervention session includes a pre-intervention assessment, continuous measurements obtained during the intervention phase, and an immediate post-intervention assessment. The primary timepoints include: (1) pre-intervention (baseline, immediately before each session), (2) during intervention (online assessment collected during the intervention), and (3) post-intervention (immediately after each session). These timepoints are assessed for all four experimental conditions, with each session separated by a 48-hour washout period.
Primary outcome [2] 344769 0
Electroencephalography (EEG) -derived brain oscillatory measures ( functional connectivity)
Timepoint [2] 344769 0
Each intervention session includes a pre-intervention assessment, continuous measurements obtained during the intervention phase, and an immediate post-intervention assessment. The primary timepoints include: (1) pre-intervention (baseline, immediately before each session), (2) during intervention (online assessment collected during the intervention), and (3) post-intervention (immediately after each session). These timepoints are assessed for all four experimental conditions, with each session separated by a 48-hour washout period.
Secondary outcome [1] 457747 0
Pain sensitivity-Pain threshold (PTh)
Timepoint [1] 457747 0
Each intervention session includes two assessment timepoints: a pre-intervention assessment (immediately before the intervention) and an immediate post-intervention assessment (immediately after the intervention). These timepoints are assessed for all four experimental conditions, with each session separated by a 48-hour washout period.
Secondary outcome [2] 459137 0
Pain sensitivity-Pain tolerance (PTol)
Timepoint [2] 459137 0
Each intervention session includes two assessment timepoints: a pre-intervention assessment (immediately before the intervention) and an immediate post-intervention assessment (immediately after the intervention). These timepoints are assessed for all four experimental conditions, with each session separated by a 48-hour washout period.
Secondary outcome [3] 460351 0
Cognitive performance
Timepoint [3] 460351 0
Each intervention session includes two assessment timepoints: a pre-intervention assessment (immediately before the intervention) and an immediate post-intervention assessment (immediately after the intervention).

Eligibility
Key inclusion criteria
Participants were eligible if they were between the ages of 18 and 40, had normal cognitive function, no history of neurological or psychiatric conditions, no contraindications to an EEG, and were not taking neuroactive medications.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Exclusion criteria included the presence of metallic implants in the head, indwelling body stimulators, a history of seizures, or current pregnancy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures with sealed opaque envelopes)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (with computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321066 0
University
Name [1] 321066 0
Monash University
Country [1] 321066 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 323772 0
None
Name [1] 323772 0
Address [1] 323772 0
Country [1] 323772 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319604 0
Monash University Human Research Ethics Committee
Ethics committee address [1] 319604 0
Ethics committee country [1] 319604 0
Australia
Date submitted for ethics approval [1] 319604 0
17/09/2025
Approval date [1] 319604 0
02/10/2025
Ethics approval number [1] 319604 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147834 0
Dr Huize Lin
Address 147834 0
Monash University – Peninsula Campus School of Primary and Allied Health Care Building A, 47 Moorooduc Highway Frankston, VIC 3199, Australia
Country 147834 0
Australia
Phone 147834 0
+61 0478517442
Fax 147834 0
Email 147834 0
Contact person for public queries
Name 147835 0
Huize Lin
Address 147835 0
Monash University – Peninsula Campus School of Primary and Allied Health Care Building A, 47 Moorooduc Highway Frankston, VIC 3199, Australia
Country 147835 0
Australia
Phone 147835 0
+61 0478517442
Fax 147835 0
Email 147835 0
Contact person for scientific queries
Name 147836 0
Huize Lin
Address 147836 0
Monash University – Peninsula Campus School of Primary and Allied Health Care Building A, 47 Moorooduc Highway Frankston, VIC 3199, Australia
Country 147836 0
Australia
Phone 147836 0
+61 0478517442
Fax 147836 0
Email 147836 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    ethics.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.